Roginolisib posts early activity in metastatic uveal melanoma as iOnctura pushes PI3K delta into solid tumors
Merck KGaA-backed iOnctura is taking a selective PI3K delta inhibitor into one of oncology’s most difficult settings: metastatic uveal melanoma.
The phase 1 signal is still early, but it is hard to ignore. Across 44 patients with advanced solid and hematologic malignancies, treatment with roginolisib was associated with a median overall survival of 20.8 months, a figure that stands in sharp contrast to the roughly seven-month historical benchmark cited for patients who receive immunotherapies as second-line treatment. There was no placebo comparator in the study, so the comparison cannot be treated as a direct head-to-head result. Even so, in a disease where rapid progression is common and options narrow quickly after first-line therapy, a survival signal of this size draws immediate attention.
The study was split into two parts. Part A enrolled 24 patients in a dose-escalation phase, while part B expanded into 20 patients with metastatic uveal melanoma receiving roginolisib as a second-line treatment. Across the full cohort, safety remained manageable. No dose-limiting toxicities were observed, no dose modifications were required, and grade 3 adverse events occurred in three of 44 patients.
That tolerability profile matters because PI3K inhibition has often been constrained by toxicity, particularly in settings where patients are already fragile from prior treatment. A compound that can stay on board without forcing dose changes has a better chance of sustaining pathway suppression long enough to matter biologically. In a tumor that spreads aggressively and tends to seed the liver, treatment interruptions can erase a narrow therapeutic window.
Roginolisib also showed the kind of pharmacodynamic behavior developers want to see when they move from mechanism to clinic. The drug produced a predictable pharmacokinetic profile and reduced regulatory T-cell abundance while increasing activated CD8+ T cells. In plain clinical terms, the agent appears to be doing two things at once: dampening an immunosuppressive compartment and shifting the immune balance toward cytotoxic activity. For metastatic uveal melanoma, where immune escape is a major obstacle, that dual effect provides a biologically coherent explanation for why the program is being advanced.
A selective PI3K delta strategy built around immune reprogramming
The biological rationale rests on the PI3K signaling pathway, one of the most frequently dysregulated pathways across multiple cancer types, including uveal melanoma. Cancer cells receive extracellular signals that bind to receptors and trigger the PI3K cascade, leading to production of the second messenger PIP3 and activation of downstream signaling programs that support cancer growth and survival. In this context, the target is not simply proliferation in the abstract. It is also the immune environment surrounding the tumor.
iOnctura selected an indication where immunosuppression was believed to drive the malignancy. That choice is central to how the company is positioning roginolisib. Rather than using PI3K delta purely as a tumor-cell growth target, the strategy depends on relieving immunosuppression in the microenvironment and reawakening anti-tumor immunity. Catherine Pickering, Ph.D., the company’s CEO, said the program is aimed at patients who progress rapidly and often have nothing left after progression. She argued that roginolisib fits where there is a need for added life without added burden.
The agent itself is designed as an oral conformation stabilizer of the inactive form of PI3K delta. It binds a unique site in the inactive state, causes a conformational shift, blocks ATP from binding, and prevents the enzyme from flipping into the activated state. That mechanism is important because it speaks to selectivity and durability, two features that often decide whether a pathway inhibitor can stay useful outside the lab.
Alongside the phase 1 findings, iOnctura published mechanistic work comparing roginolisib with Gilead’s idelalisib, another PI3K delta inhibitor. In tumor samples from patients with chronic lymphocytic leukemia, roginolisib was linked to more sustained suppression of PIP3 formation. The paper also described the binding mechanism in detail. While those data came from a different disease context, they reinforce the same theme: roginolisib is not just another PI3K-class agent, but one with a distinct binding behavior that may support prolonged pathway suppression.
The solid-tumor opening is narrow, but the class context is shifting
The broader PI3K class already includes several approved drugs, yet the field has remained uneven. Besides idelalisib, there is Secura Bio’s duvelisib, a dual PI3K delta and gamma inhibitor approved for B-cell blood cancers, and Pharming Group’s Novartis-licensed selective PI3K delta inhibitor Joenja, approved for a rare genetic immune disorder. PI3K alpha inhibitors such as Novartis’ Piqray and Roche’s Itovebi are approved in breast cancer. What does not exist is an approved PI3K delta inhibitor for a solid tumor indication.
That gap is the opportunity iOnctura is trying to exploit. Metastatic uveal melanoma is a logical if unforgiving test case because the disease remains biologically distinctive and clinically lethal once it spreads. The liver is a common site of spread, and outcomes after relapse are poor enough that even modest changes in survival and immune activity can become meaningful. The current data do not establish efficacy on their own, but they do show the combination of tolerability, immune modulation, and a survival figure that will likely justify more study.
A direct comparison against historical immunotherapy outcomes is not proof, yet it is enough to sharpen the next question. Can selective PI3K delta inhibition do more than suppress a pathway in tumor samples? Can it shift the microenvironment in a way that translates into durable control in a disease that usually advances quickly even on treatment? For now, roginolisib has opened the door. The unanswered work is whether the signal holds as the program moves beyond phase 1 and into a larger solid-tumor experience.